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Abstract
Background: The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)
and the Tyrer-Cuzick breast cancer risk prediction models are commonly used in clinical practice and have recently
been extended to include polygenic risk scores (PRS). In addition, BOADICEA has also been extended to include
reproductive and lifestyle factors, which were already part of Tyrer-Cuzick model. We conducted a comparative
prospective validation of these models after incorporating the recently developed 313-variant PRS.
Methods: Calibration and discrimination of 5-year absolute risk was assessed in a nested case-control sample of
1337 women of European ancestry (619 incident breast cancer cases) aged 23–75 years from the Generations Study.
Results: The extended BOADICEA model with reproductive/lifestyle factors and PRS was well calibrated across risk
deciles; expected-to-observed ratio (E/O) at the highest risk decile :0.97 (95 % CI 0.51 − 1.86) for women younger
than 50 years and 1.09 (0.66 − 1.80) for women 50 years or older. Adding reproductive/lifestyle factors and PRS to
the BOADICEA model improved discrimination modestly in younger women (area under the curve (AUC) 69.7 % vs.
69.1%) and substantially in older women (AUC 64.6 % vs. 56.8%). The Tyrer-Cuzick model with PRS showed evidence
of overestimation at the highest risk decile: E/O = 1.54(0.81 − 2.92) for younger and 1.73 (1.03 − 2.90) for older women.
Conclusion: The extended BOADICEA model identified women in a European-ancestry population at elevated breast
cancer risk more accurately than the Tyrer-Cuzick model with PRS. With the increasing availability of PRS, these analyses
can inform choice of risk models incorporating PRS for risk stratified breast cancer prevention among women of
European ancestry.
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Introduction
The Breast and Ovarian Analysis of Disease and Carrier
Estimation Algorithm (BOADICEA) breast cancer model
was originally developed to predict breast cancer risk for
women using pedigree-level family history information
and genetic testing results on rare pathogenic variants in
high and moderate risk genes [1, 2]. This model has
been updated (version 5.0) to include reproductive and
lifestyle factors and the recently developed polygenic risk
score (PRS) based on 313 common germline variants [3]
for applications in both general and high-risk popula-
tions [4, 5]. The Tyrer-Cuzick or International Breast
Intervention Study (IBIS) model [6], commonly used in
clinical and research settings, also includes extensive
family history and comprehensive risk factor information
and has been updated to include information on PRS.
We recently evaluated the performance of the Tyrer-
Cuzick model (version 8.0) without PRS in a prospective
cohort of women of European ancestry in the general
population [7]. Here, we perform a comparative valid-
ation of the extended BOADICEA and Tyrer-Cuzick
models incorporating the 313-variant PRS in the same
prospective cohort.
The original BOADICEA and Tyrer-Cuzick models
are considered in clinical guidelines [8, 9] for manage-
ment of women with a family history of breast cancer
and have been implemented in user-friendly risk assess-
ment tools that can incorporate PRS (BOADICEA:
https://canrisk.org; IBIS: https://ibis.ikonopedia.com).
Assessment of disease risk using PRS has been increas-
ingly commercially available through genetic services
and marketed to clinicians [10]. Given the widespread
use of these models and their capabilities to incorporate
PRS with other risk factors in flexible risk prediction
tools, comparative prospective validation of these models
and their extensions is critical to assess their ability to
accurately identify women at different risk levels for
risk-stratified screening, surveillance or prevention
strategies.
We report results from a prospective comparative val-
idation of the extended BOADICEA model (v.5) with
risk factors and 313-variant PRS and Tyrer-Cuzick
model (v.8) with the same PRS in the Generations Study,
a population-based cohort study of UK women [11].
Methods
Data were used from a nested case-control sample
within the Generations Study (2003–2012), a prospective
cohort of over 113,000 UK women aged 16–102 years;
details are elsewhere [7, 11]. The comparative validation
analyses of 5-year absolute risk of breast cancer were
based on 1337 women aged 23–75 years, including 619
incident breast cancer patients within 5 years from study
recruitment, with information on the PRS and the risk
factors used in both the BOADICEA (v.5) and Tyrer-
Cuzick (v.8) models (Supplementary Fig. 1). Supplementary
Table 1 summarizes the information on questionnaire-
based risk factors and 313-variant PRS for these women.
To update the original BOADICEA model, the relative
risks for the risk factors and PRS were derived using the
literature-based approach [3, 7]; further details are given
in Lee et al. [4]. In this model, the family history associ-
ation, described by a residual polygenic component, was
adjusted to account for the PRS explaining ~ 20% of the
breast cancer familial aggregation. The PRS was added
to the Tyrer-Cuzick model (v.8) using the approach de-
scribed in Brentnall et al. [12], where the associations of
family history and PRS were unadjusted and assumed to
be multiplicative on the risk of developing breast cancer.
The comparative validation analyses were performed
using the standardized model calibration and discrimin-
ation methods implemented in the Individualized Coher-
ent Absolute Risk Estimator (iCARE) tool [13] (details in
supplement). Briefly, model calibration was assessed in
terms of relative and absolute risk by comparing the ob-
served and expected quantities, overall, and within risk
categories. The area under the curve (AUC) was esti-
mated to assess model discrimination.
Results
For women younger than 50 years, the original and ex-
tended BOADICEA models (with PRS and with PRS and
reproductive/lifestyle factors) showed good calibration of
relative and absolute risk (Fig. 1). At the highest decile
of predicted 5-year absolute risk, the extended model
with PRS and reproductive/lifestyle factors showed bet-
ter calibration than both the original model and the ex-
tended model with PRS only, with a ratio of expected to
observed number of cases (E/O) of 0.97 [95% confidence
interval (CI) 0.51 − 1.86], 0.83 (0.44 − 1.56), 0.85 (0.44 −
1.63), respectively. Adding PRS and risk factors led to
modest improvement in AUC from 69.1 % (63.5 % −
74.6%) to 69.7 % (64.1 % − 75.2%). Incorporating risk fac-
tors did not improve the discrimination of the original
model (data not shown) or the extended model with
PRS (Fig. 1). The Tyrer-Cuzick model with PRS had
similar discrimination [AUC : 69.4 % (63.8 % − 75.0%)] to
the extended BOADICEA model with PRS and risk fac-
tors but showed evidence of overestimation at the high-
est risk decile [E/O : 1.54 (0.81 − 2.92)].
The original and extended BOADICEA models also
showed good calibration of relative and absolute risk for
women 50 years or older (Fig. 2), in particular for
women at the highest risk decile [E/O : 0.95 (0.56 − 1.62)
for the original model, 1.07 (0.63 − 1.82) for the ex-
tended model with PRS, 1.09 (0.66 − 1.80) for the ex-
tended model with PRS and risk factors]. For this age
group, incorporating PRS and risk factors led to
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substantial improvements in AUC from 56.8 % (52.9 % −
60.6%) to 64.6 % (60.9 % − 68.2%). Adding risk factors
substantially improved the risk discrimination of the ori-
ginal model (data not shown) and the extended model
with PRS (Fig. 2). The Tyrer-Cuzick model with PRS
had risk discrimination comparable to the extended
BOADICEA model with PRS and risk factors; however,
the former substantially overestimated risk for women at
the highest risk decile [E/O : 1.73 (1.03 − 2.90)]. Overesti-
mation of risk in high-risk deciles was present in models
with or without the PRS (Supplementary Fig. 2).
Discussion
Our study shows that the extended BOADICEA model,
which incorporated reproductive and lifestyle factors
and a 313-SNP PRS to the familial aggregation informa-
tion, predicted 5-year absolute risk of breast cancer
more accurately than the Tyrer-Cuzick model with the
same PRS, for women at the highest risk decile in the
Generations study, a UK-based prospective cohort.
Previous studies in populations of women of European
ancestry provided evidence of overestimation of absolute
risk obtained from the Tyrer-Cuzick model without PRS
for women in the highest risk decile [7, 14]. Two recent
studies that incorporated PRSs with fewer genetic vari-
ants to this model, showed good calibration in terms of
relative risk, but did not evaluate absolute risk calibra-
tion [12, 15]. Our results showed overestimation of the
absolute risk for women at the high-risk deciles, possibly
due to not attenuating the contribution of family history
association to account for the substantial familial aggre-
gation explained by the PRS. This can lead to inflated
breast cancer risks, particularly for women with breast
cancer family history who are more prevalent in high-
risk deciles. Accounting for the correlation between the
PRS and family history would likely reduce this overesti-
mation and future studies are needed to investigate the
extent of this reduction.
Strengths of the current analyses include the use of
the Generations Study, a relatively recent population-
based cohort with a wide range of ages of participating
women and the comparison of two widely used risk pre-
diction tools that can incorporate PRS. With the increas-
ing availability of PRS (e.g., in countries like US), such
rigorous comparative evaluation of models incorporating
PRS with other risk factor information is critical to
Fig. 1 Calibration and discrimination of 5-year risk predictions of breast cancer for women younger than 50 years in the nested case-control
sample of the Generations Study cohort with risk categories based on deciles of predicted 5-year absolute risk. Validation results are shown for
the original BOADICEA model that incorporates pedigree level family history information, its two extensions: (i) incorporating the recently
developed PRS based on 313 common germline variants to the original model and (ii) incorporating the 313-variant PRS and reproductive and
lifestyle factors to the original model, and the IBIS (Version 8.0) model after including the 313-variant PRS. Estimates and 95% CI of the calibration
slope and intercept are reported based on a linear regression of the decile-specific observed proportion of cases within 5 years and the average
of the predicted 5-year absolute risk. AUC = area under the curve, c2 =chi-square goodness-of-fit test, BOADICEA = Breast and Ovarian Analysis of
Disease Incidence and Carrier Estimation Algorithm, IBIS = International Breast Cancer Intervention Study, PRS = polygenic risk score, E/O =
expected to observed number of cases, CI = confidence interval
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assess their suitability in clinical and research applica-
tions. Moreover, model calibration was assessed both
overall and within risk categories, in particular for
women at the extremes of risk for whom prevention and
screening are most relevant. The CanRisk tool has
already implemented the BOADICEA model and its ex-
tensions. The current study provides some evidence of
accurate risk predictions from this tool for the UK gen-
eral population. Further evaluation of this tool in both
general and high-risk populations is needed before wide-
spread clinical applications. Moreover, future research is
merited towards risk model building and validation for
women of non-European ancestry.
To summarize, the extended BOADICEA model with
PRS and reproductive/lifestyle factors identified women
of European ancestry at elevated 5-year risk of breast
cancer more accurately than the Tyrer-Cuzick model
with PRS. As disease risk prediction with PRS is becom-
ing more available through genetic services in some
countries (e.g., the USA), these and other similar ana-
lyses will potentially inform the choice of risk models for
developing risk-stratified breast cancer prevention and
screening strategies for women of European ancestry.
Supplementary Information
The online version contains supplementary material available at https://doi.
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Additional file 1: Supplementary Materials: Comparative validation
of the BOADICEA and Tyrer- Cuzick breast cancer risk models
incorporating classical risk factors and polygenic risk in a population-
based prospective cohort of women of European ancestry.Additional de-
tails on the definition of study follow-up, sources of genotype data, risk
factors in BOADICEA and Tyrer-Cuzick models, model validation methods
are given. Supplementary Fig. 1. shows the study design in the valid-
ation cohort. Supplementary Fig. 2. shows a comparative validation of
Tyrer-Cuzick model with and without PRS in the Generations Study. Sup-
plementary Table 1 shows the risk factor distribution in the Generation
Study. Figure 1. Calibration and discrimination of five-year risk predictions
of breast cancer for women younger than 50 years in the nested case-
control sample of the Generations Study cohort with risk categories
based on deciles of predicted five-year absolute risk. Figure 2. Calibration
and discrimination of five-year risk predictions of breast cancer for
women aged 50 years or older in the nested case-control sample of the
Generations Study cohort with risk categories based on deciles of pre-
dicted five-year absolute risk.
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